Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

sklb1028

sklb1028 is a epidermal growth factor receptor erbb1 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — sklb1028
Class
—
Route
—
Patents
0
Programs
2
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

sklb1028 is a epidermal growth factor receptor erbb1 inhibitor.

Key facts

INN sklb1028
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor

Mechanism of action

Epidermal growth factor receptor erbB1 inhibitor

Primary target: Epidermal growth factor receptor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. B10 L-BPA Injection Phase 2 · Heron Therapeutics · Meningioma
  2. B10 L-BPA Injection Phase 2 · Heron Therapeutics · Malignant Brain Tumors

Related & competitor drugs

Browse all drugs
  1. erlotinib hydrochloride Epidermal growth factor receptor erbB1 inhibitor
  2. lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor
  3. mobocertinib Antineoplastic and immunomodulating agents (L01)
  4. mobocertinib succinate Epidermal growth factor receptor erbB1 inhibitor
  5. neratinib maleate Receptor protein-tyrosine kinase erbB-2 inhibitor
  6. afatinib dimaleate Epidermal growth factor receptor erbB1 inhibitor

Frequently asked questions

What is sklb1028?

sklb1028 is a epidermal growth factor receptor erbb1 inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.